Hepatocarcinoma: from pathogenic mechanisms to target therapy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-11-17

AUTHORS

Luigi Manzione, Antonio Maria Grimaldi, Rosangela Romano, Domenica Ferrara, Angelo Dinota

ABSTRACT

Hepatocellular carcinoma (HCC) is among the most prevalent and lethal cancers worldwide. It is currently estimated that there are 14,000–18,000 new cases of hepatocellular carcinoma in the United States each year. It is often difficult to identify individuals at risk for HCC. The main associated diseases are chronic hepatitis B and chronic hepatitis C viral infections. While a significant number of potential mutations have been generated including p53 and Insulin-like Growth Factor, our understanding of the molecular mechanisms driving the genesis and progression of HCC remain limited. HCC screening is recommended in high-risk patients. High-risk patients include virtually all patients with cirrhosis and some HBV-infected patients irrespective of cirrhosis (>40 years in men and >50 years in women). A diagnostic approach to HCC has been developed incorporating serology, cytohistology, and radiological characteristics. A precise staging of the disease may help decide on prognosis as well as choice of therapy with the greatest survival potential. Liver transplantation, in theory, is the optimal therapeutic option for HCC; it simultaneously removes the tumor and underlying cirrhosis thus minimizing the risk of HCC recurrence. When it is impossible for this to be performed, percutaneous ablation, chemoembolization, chemotherapy and the newer molecular therapies can be used. Sorafenib is the only drug registered today for the treatment of advanced HCC. More... »

PAGES

214-222

References to SciGraph publications

  • 1998-12-01. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C in THE AMERICAN JOURNAL OF GASTROENTEROLOGY
  • 2006-06-26. RNA interference-mediated prevention and therapy for hepatocellular carcinoma in ONCOGENE
  • 2006-06-26. Dysregulation of growth factor signaling in human hepatocellular carcinoma in ONCOGENE
  • 2002-03-01. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience) in THE AMERICAN JOURNAL OF GASTROENTEROLOGY
  • 2006-06-26. New aspects of diagnosis and therapy of hepatocellular carcinoma in ONCOGENE
  • 1991-03. Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients in WORLD JOURNAL OF SURGERY
  • 2003-03-01. Screening for Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis: A Cost-Utility Analysis in THE AMERICAN JOURNAL OF GASTROENTEROLOGY
  • 2004-03-20. Randomized controlled trial of screening for hepatocellular carcinoma in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2006-12-08. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2007-05-23. The Clinical Outcome of Small (<20 mm) Arterially Enhancing Nodules on MRI in the Cirrhotic Liver in THE AMERICAN JOURNAL OF GASTROENTEROLOGY
  • 2004-07-10. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s12156-008-0077-x

    DOI

    http://dx.doi.org/10.1007/s12156-008-0077-x

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1011613709


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Division of Oncology, A.O. S. Carlo, Potenza, Italy", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Division of Oncology, A.O. S. Carlo, Potenza, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Manzione", 
            "givenName": "Luigi", 
            "id": "sg:person.01260533117.65", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260533117.65"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Oncology, A.O. S. Carlo, Potenza, Italy", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Division of Oncology, A.O. S. Carlo, Potenza, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Grimaldi", 
            "givenName": "Antonio Maria", 
            "id": "sg:person.0762462504.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762462504.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Oncology, A.O. S. Carlo, Potenza, Italy", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Division of Oncology, A.O. S. Carlo, Potenza, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Romano", 
            "givenName": "Rosangela", 
            "id": "sg:person.0756667065.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756667065.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Oncology, A.O. S. Carlo, Potenza, Italy", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Division of Oncology, A.O. S. Carlo, Potenza, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ferrara", 
            "givenName": "Domenica", 
            "id": "sg:person.01266456053.12", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266456053.12"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Oncology, A.O. S. Carlo, Potenza, Italy", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Division of Oncology, A.O. S. Carlo, Potenza, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dinota", 
            "givenName": "Angelo", 
            "id": "sg:person.01044167051.02", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044167051.02"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00280-004-0837-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047246165", 
              "https://doi.org/10.1007/s00280-004-0837-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1111/j.1572-0241.2003.07327.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052598709", 
              "https://doi.org/10.1111/j.1572-0241.2003.07327.x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1209556", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053442620", 
              "https://doi.org/10.1038/sj.onc.1209556"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-006-0393-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011237772", 
              "https://doi.org/10.1007/s00280-006-0393-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1209548", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049481763", 
              "https://doi.org/10.1038/sj.onc.1209548"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1111/j.1572-0241.2002.05557.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037322870", 
              "https://doi.org/10.1111/j.1572-0241.2002.05557.x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1209549", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044781344", 
              "https://doi.org/10.1038/sj.onc.1209549"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1111/j.1572-0241.1998.00703.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027245911", 
              "https://doi.org/10.1111/j.1572-0241.1998.00703.x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1111/j.1572-0241.2007.01338.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027570971", 
              "https://doi.org/10.1111/j.1572-0241.2007.01338.x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01659064", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049278373", 
              "https://doi.org/10.1007/bf01659064"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00432-004-0552-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005026117", 
              "https://doi.org/10.1007/s00432-004-0552-0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2008-11-17", 
        "datePublishedReg": "2008-11-17", 
        "description": "Hepatocellular carcinoma (HCC) is among the most prevalent and lethal cancers worldwide. It is currently estimated that there are 14,000\u201318,000 new cases of hepatocellular carcinoma in the United States each year. It is often difficult to identify individuals at risk for HCC. The main associated diseases are chronic hepatitis B and chronic hepatitis C viral infections. While a significant number of potential mutations have been generated including p53 and Insulin-like Growth Factor, our understanding of the molecular mechanisms driving the genesis and progression of HCC remain limited. HCC screening is recommended in high-risk patients. High-risk patients include virtually all patients with cirrhosis and some HBV-infected patients irrespective of cirrhosis (>40 years in men and >50 years in women). A diagnostic approach to HCC has been developed incorporating serology, cytohistology, and radiological characteristics. A precise staging of the disease may help decide on prognosis as well as choice of therapy with the greatest survival potential. Liver transplantation, in theory, is the optimal therapeutic option for HCC; it simultaneously removes the tumor and underlying cirrhosis thus minimizing the risk of HCC recurrence. When it is impossible for this to be performed, percutaneous ablation, chemoembolization, chemotherapy and the newer molecular therapies can be used. Sorafenib is the only drug registered today for the treatment of advanced HCC.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s12156-008-0077-x", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1042565", 
            "issn": [
              "1970-5557", 
              "1970-5565"
            ], 
            "name": "Oncology Reviews", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "4", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "2"
          }
        ], 
        "keywords": [
          "high-risk patients", 
          "hepatocellular carcinoma", 
          "chronic hepatitis C viral infection", 
          "hepatitis C viral infection", 
          "insulin-like growth factor", 
          "chronic hepatitis B", 
          "optimal therapeutic option", 
          "choice of therapy", 
          "advanced hepatocellular carcinoma", 
          "progression of HCC", 
          "new molecular therapies", 
          "liver transplantation", 
          "hepatitis B", 
          "percutaneous ablation", 
          "HCC recurrence", 
          "therapeutic options", 
          "only drug", 
          "radiological characteristics", 
          "precise staging", 
          "HCC screening", 
          "pathogenic mechanisms", 
          "lethal cancer", 
          "viral infection", 
          "new cases", 
          "patients", 
          "molecular therapy", 
          "cirrhosis", 
          "diagnostic approach", 
          "therapy", 
          "growth factor", 
          "greater survival potential", 
          "carcinoma", 
          "disease", 
          "significant number", 
          "risk", 
          "molecular mechanisms", 
          "potential mutations", 
          "chemoembolization", 
          "HBV", 
          "chemotherapy", 
          "transplantation", 
          "prognosis", 
          "recurrence", 
          "serology", 
          "sorafenib", 
          "staging", 
          "tumors", 
          "survival potential", 
          "cancer", 
          "infection", 
          "progression", 
          "cytohistology", 
          "drugs", 
          "treatment", 
          "United States", 
          "ablation", 
          "p53", 
          "screening", 
          "options", 
          "years", 
          "mechanism", 
          "individuals", 
          "mutations", 
          "factors", 
          "cases", 
          "genesis", 
          "number", 
          "choice", 
          "potential", 
          "understanding", 
          "characteristics", 
          "approach", 
          "state", 
          "today", 
          "theory", 
          "C viral infections"
        ], 
        "name": "Hepatocarcinoma: from pathogenic mechanisms to target therapy", 
        "pagination": "214-222", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1011613709"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s12156-008-0077-x"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s12156-008-0077-x", 
          "https://app.dimensions.ai/details/publication/pub.1011613709"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T18:19", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_470.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s12156-008-0077-x"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12156-008-0077-x'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12156-008-0077-x'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12156-008-0077-x'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12156-008-0077-x'


     

    This table displays all metadata directly associated to this object as RDF triples.

    206 TRIPLES      22 PREDICATES      112 URIs      93 LITERALS      6 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s12156-008-0077-x schema:about anzsrc-for:11
    2 anzsrc-for:1112
    3 schema:author Nda903aa47e2747f0b9a3df0d52f73bd4
    4 schema:citation sg:pub.10.1007/bf01659064
    5 sg:pub.10.1007/s00280-004-0837-7
    6 sg:pub.10.1007/s00280-006-0393-4
    7 sg:pub.10.1007/s00432-004-0552-0
    8 sg:pub.10.1038/sj.onc.1209548
    9 sg:pub.10.1038/sj.onc.1209549
    10 sg:pub.10.1038/sj.onc.1209556
    11 sg:pub.10.1111/j.1572-0241.1998.00703.x
    12 sg:pub.10.1111/j.1572-0241.2002.05557.x
    13 sg:pub.10.1111/j.1572-0241.2003.07327.x
    14 sg:pub.10.1111/j.1572-0241.2007.01338.x
    15 schema:datePublished 2008-11-17
    16 schema:datePublishedReg 2008-11-17
    17 schema:description Hepatocellular carcinoma (HCC) is among the most prevalent and lethal cancers worldwide. It is currently estimated that there are 14,000–18,000 new cases of hepatocellular carcinoma in the United States each year. It is often difficult to identify individuals at risk for HCC. The main associated diseases are chronic hepatitis B and chronic hepatitis C viral infections. While a significant number of potential mutations have been generated including p53 and Insulin-like Growth Factor, our understanding of the molecular mechanisms driving the genesis and progression of HCC remain limited. HCC screening is recommended in high-risk patients. High-risk patients include virtually all patients with cirrhosis and some HBV-infected patients irrespective of cirrhosis (>40 years in men and >50 years in women). A diagnostic approach to HCC has been developed incorporating serology, cytohistology, and radiological characteristics. A precise staging of the disease may help decide on prognosis as well as choice of therapy with the greatest survival potential. Liver transplantation, in theory, is the optimal therapeutic option for HCC; it simultaneously removes the tumor and underlying cirrhosis thus minimizing the risk of HCC recurrence. When it is impossible for this to be performed, percutaneous ablation, chemoembolization, chemotherapy and the newer molecular therapies can be used. Sorafenib is the only drug registered today for the treatment of advanced HCC.
    18 schema:genre article
    19 schema:inLanguage en
    20 schema:isAccessibleForFree false
    21 schema:isPartOf N4ad637b9eeae477c85756adbd933dddf
    22 N77ae87585774414688134d6cd23de4c3
    23 sg:journal.1042565
    24 schema:keywords C viral infections
    25 HBV
    26 HCC recurrence
    27 HCC screening
    28 United States
    29 ablation
    30 advanced hepatocellular carcinoma
    31 approach
    32 cancer
    33 carcinoma
    34 cases
    35 characteristics
    36 chemoembolization
    37 chemotherapy
    38 choice
    39 choice of therapy
    40 chronic hepatitis B
    41 chronic hepatitis C viral infection
    42 cirrhosis
    43 cytohistology
    44 diagnostic approach
    45 disease
    46 drugs
    47 factors
    48 genesis
    49 greater survival potential
    50 growth factor
    51 hepatitis B
    52 hepatitis C viral infection
    53 hepatocellular carcinoma
    54 high-risk patients
    55 individuals
    56 infection
    57 insulin-like growth factor
    58 lethal cancer
    59 liver transplantation
    60 mechanism
    61 molecular mechanisms
    62 molecular therapy
    63 mutations
    64 new cases
    65 new molecular therapies
    66 number
    67 only drug
    68 optimal therapeutic option
    69 options
    70 p53
    71 pathogenic mechanisms
    72 patients
    73 percutaneous ablation
    74 potential
    75 potential mutations
    76 precise staging
    77 prognosis
    78 progression
    79 progression of HCC
    80 radiological characteristics
    81 recurrence
    82 risk
    83 screening
    84 serology
    85 significant number
    86 sorafenib
    87 staging
    88 state
    89 survival potential
    90 theory
    91 therapeutic options
    92 therapy
    93 today
    94 transplantation
    95 treatment
    96 tumors
    97 understanding
    98 viral infection
    99 years
    100 schema:name Hepatocarcinoma: from pathogenic mechanisms to target therapy
    101 schema:pagination 214-222
    102 schema:productId N4b0caacfd5e74f55982be8921bf36fa5
    103 N807eb0d3cbb844f786b68fe3afb3df11
    104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011613709
    105 https://doi.org/10.1007/s12156-008-0077-x
    106 schema:sdDatePublished 2022-01-01T18:19
    107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    108 schema:sdPublisher Nfb809ac70a2349588821a3916485a381
    109 schema:url https://doi.org/10.1007/s12156-008-0077-x
    110 sgo:license sg:explorer/license/
    111 sgo:sdDataset articles
    112 rdf:type schema:ScholarlyArticle
    113 N3967cee563044ae9adbaab5851a8cb16 rdf:first sg:person.01266456053.12
    114 rdf:rest N46b348d81355427d98239e33c09dda90
    115 N46b348d81355427d98239e33c09dda90 rdf:first sg:person.01044167051.02
    116 rdf:rest rdf:nil
    117 N4ad637b9eeae477c85756adbd933dddf schema:issueNumber 4
    118 rdf:type schema:PublicationIssue
    119 N4b0caacfd5e74f55982be8921bf36fa5 schema:name dimensions_id
    120 schema:value pub.1011613709
    121 rdf:type schema:PropertyValue
    122 N6a558362363743a986f97c03feb6b2a1 rdf:first sg:person.0762462504.03
    123 rdf:rest N7e8c883314164dfaa9d3df40d96b222a
    124 N77ae87585774414688134d6cd23de4c3 schema:volumeNumber 2
    125 rdf:type schema:PublicationVolume
    126 N7e8c883314164dfaa9d3df40d96b222a rdf:first sg:person.0756667065.47
    127 rdf:rest N3967cee563044ae9adbaab5851a8cb16
    128 N807eb0d3cbb844f786b68fe3afb3df11 schema:name doi
    129 schema:value 10.1007/s12156-008-0077-x
    130 rdf:type schema:PropertyValue
    131 Nda903aa47e2747f0b9a3df0d52f73bd4 rdf:first sg:person.01260533117.65
    132 rdf:rest N6a558362363743a986f97c03feb6b2a1
    133 Nfb809ac70a2349588821a3916485a381 schema:name Springer Nature - SN SciGraph project
    134 rdf:type schema:Organization
    135 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    136 schema:name Medical and Health Sciences
    137 rdf:type schema:DefinedTerm
    138 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    139 schema:name Oncology and Carcinogenesis
    140 rdf:type schema:DefinedTerm
    141 sg:journal.1042565 schema:issn 1970-5557
    142 1970-5565
    143 schema:name Oncology Reviews
    144 schema:publisher Springer Nature
    145 rdf:type schema:Periodical
    146 sg:person.01044167051.02 schema:affiliation grid-institutes:None
    147 schema:familyName Dinota
    148 schema:givenName Angelo
    149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044167051.02
    150 rdf:type schema:Person
    151 sg:person.01260533117.65 schema:affiliation grid-institutes:None
    152 schema:familyName Manzione
    153 schema:givenName Luigi
    154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260533117.65
    155 rdf:type schema:Person
    156 sg:person.01266456053.12 schema:affiliation grid-institutes:None
    157 schema:familyName Ferrara
    158 schema:givenName Domenica
    159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266456053.12
    160 rdf:type schema:Person
    161 sg:person.0756667065.47 schema:affiliation grid-institutes:None
    162 schema:familyName Romano
    163 schema:givenName Rosangela
    164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756667065.47
    165 rdf:type schema:Person
    166 sg:person.0762462504.03 schema:affiliation grid-institutes:None
    167 schema:familyName Grimaldi
    168 schema:givenName Antonio Maria
    169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762462504.03
    170 rdf:type schema:Person
    171 sg:pub.10.1007/bf01659064 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049278373
    172 https://doi.org/10.1007/bf01659064
    173 rdf:type schema:CreativeWork
    174 sg:pub.10.1007/s00280-004-0837-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047246165
    175 https://doi.org/10.1007/s00280-004-0837-7
    176 rdf:type schema:CreativeWork
    177 sg:pub.10.1007/s00280-006-0393-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011237772
    178 https://doi.org/10.1007/s00280-006-0393-4
    179 rdf:type schema:CreativeWork
    180 sg:pub.10.1007/s00432-004-0552-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005026117
    181 https://doi.org/10.1007/s00432-004-0552-0
    182 rdf:type schema:CreativeWork
    183 sg:pub.10.1038/sj.onc.1209548 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049481763
    184 https://doi.org/10.1038/sj.onc.1209548
    185 rdf:type schema:CreativeWork
    186 sg:pub.10.1038/sj.onc.1209549 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044781344
    187 https://doi.org/10.1038/sj.onc.1209549
    188 rdf:type schema:CreativeWork
    189 sg:pub.10.1038/sj.onc.1209556 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053442620
    190 https://doi.org/10.1038/sj.onc.1209556
    191 rdf:type schema:CreativeWork
    192 sg:pub.10.1111/j.1572-0241.1998.00703.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1027245911
    193 https://doi.org/10.1111/j.1572-0241.1998.00703.x
    194 rdf:type schema:CreativeWork
    195 sg:pub.10.1111/j.1572-0241.2002.05557.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037322870
    196 https://doi.org/10.1111/j.1572-0241.2002.05557.x
    197 rdf:type schema:CreativeWork
    198 sg:pub.10.1111/j.1572-0241.2003.07327.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1052598709
    199 https://doi.org/10.1111/j.1572-0241.2003.07327.x
    200 rdf:type schema:CreativeWork
    201 sg:pub.10.1111/j.1572-0241.2007.01338.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1027570971
    202 https://doi.org/10.1111/j.1572-0241.2007.01338.x
    203 rdf:type schema:CreativeWork
    204 grid-institutes:None schema:alternateName Division of Oncology, A.O. S. Carlo, Potenza, Italy
    205 schema:name Division of Oncology, A.O. S. Carlo, Potenza, Italy
    206 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...